CD155-TIGIT Axis as a Therapeutic Target for Cancer Immunotherapy

Curr Med Chem. 2024;31(13):1634-1645. doi: 10.2174/0929867330666230324152532.

Abstract

Immune checkpoint inhibitors (ICIs) have shown unprecedented efficacy in treating many advanced cancers. Although FDA-approved ICIs have shown promising efficacy in treating many advanced cancers, their application is greatly limited by the low response rate, immune-related adverse events (irAE), and drug resistance. Developing novel ICIs holds great promise to improve the survival and prognosis of advanced cancer patients. T-Cell immunoglobulin and ITIM domain (TIGIT) is an inhibitory receptor expressed on T cells, natural killer (NK) cells, and T regulatory cells. Increasing reports have shown that the disrupting CD155-TIGIT axis could activate the immune system and restore antitumor immune response. This review briefly summarized the role of TIGIT in tumor immune escape and targeting CD155-TIGIT axis drugs in preclinical and clinical trials for cancer immunotherapy.

Keywords: CD155; PD-1; TIGIT; cancer immunotherapy; immune checkpoint inhibitor; tumor cells..

Publication types

  • Review

MeSH terms

  • Animals
  • Humans
  • Immune Checkpoint Inhibitors / therapeutic use
  • Immunotherapy*
  • Neoplasms* / drug therapy
  • Neoplasms* / immunology
  • Neoplasms* / therapy
  • Receptors, Immunologic* / antagonists & inhibitors
  • Receptors, Immunologic* / immunology
  • Receptors, Immunologic* / metabolism
  • Receptors, Virus / antagonists & inhibitors
  • Receptors, Virus / immunology
  • Receptors, Virus / metabolism

Substances

  • Receptors, Immunologic
  • TIGIT protein, human
  • Receptors, Virus
  • poliovirus receptor
  • Immune Checkpoint Inhibitors